BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/2/2016 3:27:00 PM | Browse: 1026 | Download: 1427
 |
Received |
|
2016-01-22 11:05 |
|
Peer-Review Started |
|
2016-01-22 18:25 |
|
To Make the First Decision |
|
2016-02-29 15:11 |
|
Return for Revision |
|
2016-03-01 16:37 |
|
Revised |
|
2016-03-12 21:44 |
|
Second Decision |
|
2016-04-13 18:05 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2016-04-22 17:23 |
|
Articles in Press |
|
2016-04-22 17:23 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2016-05-31 11:21 |
|
Publish the Manuscript Online |
|
2016-06-02 15:25 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Prediction of the effect on antihyperglycaemic action of sitagliptin by plasma active form glucagon-like peptide-1
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Akifumi Kushiyama, Takako Kikuchi, Kentaro Tanaka, Tazu Tahara, Toshiko Takao, Yukiko Onishi, Yoko Yoshida, Shoji Kawazu and Yasuhiko Iwamoto |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Akifumi Kushiyama, MD, PhD, Division of Diabetes and Metabolism, Institute for Adult Diseases, Asahi Life Foundation, 2-2-6 Nihonbashi, Bakurocho, Chuo-ku, Tokyo 103-0002, Japan. kusiyaa-tky@umin.ac.jp |
| Key Words |
Dipeptidyl peptidase-4 inhibitor; Active form glucagon-like peptide-1; Hemoglobin A1c; Regression analysis |
| Core Tip |
This clinical trials study revealed novel non-responders for the sitagliptin treatment of patients with type 2 diabetes. The fasting active form of glucagon-like peptide-1 (GLP-1) is related to Hemoglobin A1c (HbA1c) lowering and is independent of the previously reported factors associated with non-responders, such as high body mass index or low baseline HbA1c. These non-responders did not show fasting active GLP-1 elevation after sitagliptin administration, nor following ameliorated beta cell function and insulin secretion. The mechanism of poor responsiveness is still not unveiled, however, measuring active GLP-1 might be a good marker for prognosis, and may help clarifying one aspect of response variation against sitagliptin. |
| Publish Date |
2016-06-02 15:25 |
| Citation |
Kushiyama A, Kikuchi T, Tanaka K, Tahara T, Takao T, Onishi Y, Yoshida Y, Kawazu S, Iwamoto Y. Prediction of the effect on antihyperglycaemic action of sitagliptin by plasma active form glucagon-like peptide-1. World J Diabetes 2016; 7(11): 230-238 |
| URL |
http://www.wjgnet.com/1948-9358/full/v7/i11/230.htm |
| DOI |
http://dx.doi.org/10.4239/wjd.v7.i11.230 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
